VISN

Vistance Networks, Inc.
NASDAQTECHNOLOGYCOMMUNICATION EQUIPMENT

Key Statistics

Market Cap
$2.69B
P/E Ratio
EPS
$-0.11
Beta
1.99
52W High
$11.77
52W Low
$4.06
50-Day MA
$12.13
200-Day MA
$15.89
Dividend Yield
0.00%
Profit Margin
365.40%
Forward P/E
3.72
PEG Ratio
2.94

About Vistance Networks, Inc.

Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company, develops gene therapy products to treat patients with eye diseases. The company is headquartered in Stevenage, the United Kingdom.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$1.99B
Gross Profit (TTM)$935.10M
EBITDA$307.80M
Operating Margin2.22%
Return on Equity4.31%
Return on Assets1.35%
Revenue/Share (TTM)$8.88
Book Value$10.89
Price-to-Book1.06
Price-to-Sales (TTM)1.35
EV/Revenue1.285
EV/EBITDA9.83
Quarterly Earnings Growth (YoY)1697.00%
Quarterly Revenue Growth (YoY)-1.40%
Shares Outstanding$230.63M
Float$220.03M
% Insiders3.14%
% Institutions104.81%

Historical Volatility

HV 10-Day
120.76%
HV 20-Day
86.64%
HV 30-Day
72.38%
HV 60-Day
56.72%
HV Rank

Volatility is currently expanding

Analyst Ratings

Consensus ($14.67 target)
1
Buy
3
Hold

Latest News

Belden Completes Acquisition of RUCKUS Networks

ST. LOUIS--(BUSINESS WIRE)--Belden Inc. (NYSE: BDC) (“Belden” or the “Company”), a leading global supplier of specialty networking solutions, today announced that it has completed its acquisition of RUCKUS Networks (“RUCKUS”), a global provider of intelligent network solutions, from Vistance Networks (Nasdaq: VISN). RUCKUS' leading enterprise networking portfolio, including industry-leading Wi-Fi, enterprise switching capabilities and AI driven network management platforms, make Belden a preemi.

Business Wire7/1/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VISN and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More TECHNOLOGY Stocks

Data last updated: 8/18/2026